Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Real-world analysis of gilteritinib for R/R FLT3-mutated AML

Shai Shimony • 13 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Gilteritinib Venetoclax
ADMIRAL

Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, shares some key results from a real-world analysis of gilteritinib for the treatment of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Shimony discusses the overall survival (OS) observed in patients and the efficacy of this agent, as well as the importance of investigating other treatment combinations in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Shai Shimony

AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal Phase III AML trial
1:42
AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal Phase III AML trial
Shai Shimony • 8 Dec 2024
The impact of social determinants of health on overall survival in patients with AML
1:45
The impact of social determinants of health on overall survival in patients with AML
Shai Shimony • 8 Dec 2024
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
2:28
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
Shai Shimony • 8 Dec 2024
Triplet combinations in FLT3-mutated AML
1:30
Triplet combinations in FLT3-mutated AML
Shai Shimony • 13 Jun 2022

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals